RARE
Ultragenyx Pharmaceutical Inc.
NASDAQ · USHealthcareBiotechnology
$28.53-2.56%
Price as of Jul 20, 2026
RARE financials
Ultragenyx Pharmaceutical Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $673.0M | $560.2M | $434.2M | $363.3M |
| Cost of revenue | $109.0M | $76.7M | $45.2M | $28.3M |
| Gross profit | $564.0M | $483.5M | $389.0M | $335.0M |
| Operating expenses | $1.1B | $1.0B | $958.2M | $983.9M |
| Operating income | -$535.0M | -$536.0M | -$569.2M | -$648.9M |
| Net income | -$575.0M | -$569.2M | -$606.6M | -$707.4M |
| EBITDA | -$474.0M | -$469.0M | -$516.5M | -$640.5M |
| Basic EPS | $-5.83 | $-6.29 | $-8.25 | $-10.12 |
| Diluted EPS | $-5.83 | $-6.29 | $-8.25 | $-10.12 |
| Balance sheet | ||||
| Cash & equivalents | $434.0M | $173.7M | $213.6M | $132.9M |
| Total assets | $1.5B | $1.5B | $1.5B | $1.5B |
| Total liabilities | $1.6B | $1.2B | $1.2B | $1.2B |
| Stockholders’ equity | -$80.0M | $255.3M | $275.4M | $352.5M |
| Total debt | $1.3B | $40.3M | $43.2M | $31.6M |
| Net debt | $842.0M | -$133.4M | -$170.4M | -$101.4M |
| Cash flow | ||||
| Operating cash flow | -$466.0M | -$414.2M | -$474.8M | -$380.5M |
| Capital expenditure | -$6.0M | -$7.5M | -$46.8M | -$146.1M |
| Free cash flow | -$472.0M | -$421.7M | -$521.6M | -$526.6M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |